Research needed: leishmaniasis (fwd)

Patricia de Oliveira patricia at
Fri Apr 19 11:36:18 BRT 1996

--- Forwarded mail from Listas Ecologia Biologia <ecobio at Venezuela.MIT.EDU>

Date: Wed, 17 Apr 1996 15:31:26 -0400 (EDT)
From: Listas Ecologia Biologia <ecobio at Venezuela.MIT.EDU>
Subject: Research needed: leishmaniasis (fwd)

---------- Forwarded message ----------
Date: Wed, 17 Apr 96 07:17:01 -0000
From: WHO TDRNEWS <tdrnews at>
To: tdr-scientists at
Subject: Research needed: leishmaniasis

Herewith an other item of TDR News 49.

Jocelyne Bruyere, TDR Communications
(bruyerej at

------- Forwarded message

Posted: Tue, 16 Apr 96 23:00:01 -0000
Date: Wed, 17 Apr 96 07:17:01 -0000
Author: "who tdrnews"
Subject: Research needed: Leishmaniasis

[This message is converted from WPS-PLUS to ASCII]

                   RESEARCH NEEDED

LEISHMANIASIS: Call for recombinant molecules for a  "cocktail"
vaccine and testing laboratories.

The Steering Committee on Vaccines for leishmaniasis recommends
that, to help develop second generation vaccines, a group of
recombinant molecules together as a "cocktail" (rather than single
molecules independently) be considered. Choice of molecules in the
cocktail must be made on the basis of criteria such as protective
activity in experimental animals, reactivity to peripheral monocytes
from humans recovered from leishmaniasis (and assumed to be
immune), ease of production by recombinant technology, stability,
innocuity, distant from human components, etc. Participants willing
to donate their recombinant molecule(s) for collaborative research
are now being sought.

Molecules will be tested individually by one or more independent
laboratories. Following selection, the cocktail vaccine will then be
tested.  Facilities for manufacturing recombinant vaccines under
Good Manufacturing Practice are being prepared. Laboratories are
now being sought, primarily in developing/endemic countries, to test
recombinant vaccine candidates in collaboration with the SC. The
laboratories should have experience in murine experimental
leishmaniasis, special pathogen free mouse colonies, and be willing
to perform routine testing.

Those interested should contact :
Dr Farrokh Modabber, Manager, Steering Committee on Vaccines
for Leishmaniasis, WHO/TDR, 1211 Geneva, Switzerland -
Tel.(+41) 22-791-3879 - Fax: (+41) 22-791-4854.

------- End of Forwarded message

--- End of forwarded message from Listas Ecologia Biologia <ecobio at Venezuela.MIT.EDU>

Patricia de Oliveira      patricia at
Base de Dados Tropical

More information about the Leish-l mailing list